Navigation Links
Anesiva Announces Adlea ACTIVE-1 Phase 3 Clinical Results, Ceasing of Zingo Commercial Operations and Restructuring
Date:11/10/2008

y will also seek to license rights to the underlying drug delivery technology to third parties for use with other medications.

The company plans to meet with its joint venture partners in China to discuss the future of the relationship. Anesiva will restructure, suspend or cancel Zingo distribution agreements for ex-U.S. territories. In order to wind down ongoing product support obligations, Anesiva will process the withdrawal of Zingo devices from the U.S. supply chain.

As a result of the decision to cease Zingo commercial operations, the company has agreed to work with its lenders to accelerate repayment of its outstanding $20.0 million loan. In order to preserve its capital, the company will reduce its staffing to approximately 15 employees and reduce monthly expenditures to approximately $2.0 million, pending the results of the Adlea Phase 3 trial in total knee replacement surgery.

"These are difficult but necessary decisions that set a new foundation upon which to rebuild value for Anesiva's stock holders," said Michael L. Kranda, president and chief executive officer. "We look forward to the results of the Adlea Phase 3 trial in total knee arthroplasty, and pursuing partnering opportunities for this promising product candidate."

"The Anesiva Board of Directors strongly supports this new direction for Anesiva. We will continue to work closely with the company's management team to ensure Anesiva has the resources to realize its objectives," said Rodney A. Ferguson, J.D., Ph.D., Anesiva's chairman. "We thank the departing employees for their service to the company."

As a result of the foregoing, Anesiva will delay filing its quarterly report on Form 10-Q for the quarter ended September 30, 2008. The Form 10-Q will be filed as soon as reasonably practical and is expected to be filed no later than November 14, 2008.

About Adlea

Adlea is a highly purified form of capsaicin (derived from chili peppers) that acts on TRP
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company
2. Anesiva Commences Phase 2 Trial of Adlea(TM) in Arthroscopic Shoulder Surgery
3. Anesiva Announces South Korea FDA Approval of Adlea(TM) Investigational New Drug Application
4. Anesiva Announces Publication of Phase 3 Zingo(TM) Data in the Journal Pediatrics
5. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
6. Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy
7. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
8. Anesiva Defines Regulatory Pathway for Adlea with FDA
9. Anesiva Initiates Phase 2 Trial with Adlea(TM) for Pain Relief Following Total Hip Replacement Surgery
10. Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery
11. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)...  Mark Farrah Associates (MFA), www.markfarrah.com , ... the 2015 marketplace exchange projections and insights about ... According to a recent ASPE (Office of the ... Health and Human Services) report, an estimated 6.7 ... through the Marketplace as of October 2014 and ...
(Date:12/22/2014)... Dec. 22, 2014 TWi Biotechnology, Inc., ... Allowance for AC-201, TWi Biotechnology,s lead drug candidate, ... China for patent application numbered ... acceptable salts, active metabolite for treatment of type ... of treatment using AC-201 for type II diabetes, ...
(Date:12/19/2014)... 2014 You,re visiting the dentist for what ... he or she says you need a root canal. ... may have several questions and feel apprehensive about your ... it,s nothing to worry about. The Pennsylvania Dental Association ... any anxiety the public may have surrounding this common ...
Breaking Medicine Technology:Insights into the Marketplace and Individual Market Growth 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 3Root Canals Have Become More Routine 2
... Inc. announced today that it has entered into ... to provide Otsuka with access to BioWa,s POTELLIGENT® ... of their antibody therapeutics with enhanced antibody-dependent cellular ... License was initiated in May, 2007 with Takeda ...
... PEAK Surgical, Inc. and Medtronic, Inc. (NYSE: MDT ... Technologies business at Medtronic exclusive rights for global distribution ... Adenoid) tissue dissection device for the ear, nose, and ... is a major step toward our goal of capturing ...
Cached Medicine Technology:BioWa Announces Second Japanese License of POTELLIGENT(R) Technology to Otsuka Pharmaceutical 2PEAK Surgical and Medtronic Announce Global Distribution Agreement for the Ear, Nose, and Throat Market 2PEAK Surgical and Medtronic Announce Global Distribution Agreement for the Ear, Nose, and Throat Market 3
(Date:12/22/2014)... (PRWEB) December 22, 2014 The MedTech industry ... Inc, a wholly owned subsidiary of PartnerTech AB of Sweden, ... having recently achieved additional ISO Certification. , All signs point ... employment and the likelihood of a repeal of the excise ... . The industry is anticipating annual growth of 9.3% and ...
(Date:12/22/2014)... December 22, 2014 7,178 small business ... of Black Friday shopping and opted instead to join ... education company, for their 5th annual “Black Friday Boot ... just $7 to attend the 5 hour online training ... promptly donated to support two Central Texas based charities ...
(Date:12/22/2014)... Christmas is days away, and last minute gifts ... solution that will please: the Sublime Gift Card . ... $25 up to $350," says Kathy Heshelow, founder of ... wide array of skin care products and Skin Brushes." , ... , Gift delivery past shipping deadlines, or those last ...
(Date:12/22/2014)... OAK BROOK, Ill. (PRWEB) December 21, 2014 ... receive radiologist recommendations for chest computed tomography (CT) ... have clinically relevant findings, including cancer, according to ... Radiology. , Researchers said the findings show ... chest X-rays represent valuable contributions to patient care. ...
(Date:12/22/2014)... December 22, 2014 Parker & Sons, ... best in Arizona home contracting services reports a record ... its quality services in 2014. As a company that ... early 1970s, Parker and Sons is a business that ... company works side-by-side with other top quality companies in ...
Breaking Medicine News(10 mins):Health News:PartnerTech Inc. Poised for Growth in MedTech 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 3Health News:RSNA: Radiologist Recommendations for Chest CT Have High Clinical Yield 2Health News:RSNA: Radiologist Recommendations for Chest CT Have High Clinical Yield 3Health News:Parker & Sons Reports A Record Number Of Favorable References With Regard To Its Quality Services In 2014 2Health News:Parker & Sons Reports A Record Number Of Favorable References With Regard To Its Quality Services In 2014 3
... 18 Taking Control of Your Diabetes,(TCOYD) announced ... national,research firm Yankelovich that found that more than ... think that excess weight has a positive effect ... overweight often contributes,to the development of diabetes, complicates ...
... Cross asks you to help save lives by donating ... is being held on Saturday, February 21, 2009 from ... Koerner of Sewell, New Jersey. To make an ... (1-800-448-3543). (Logo: http://www.newscom.com/cgi-bin/prnh/20081216/DC52619LOGO )Koerner is battling a ...
... contest for children K-5TULSA, Okla., Feb. 18 There ... sixth annual Be Smart--Don,t Start! storyboard contest, ... of tobacco use. Request free contest materials and information ... be postmarked by Feb. 27.Sponsored by the American Lung ...
... 2009 Takeda Pharmaceutical Company Limited and its wholly-owned ... the United States Food and Drug Administration (FDA) has ... the chronic management of hyperuricemia in patients with gout. ... option in more than 40 years for the more ...
... the journal Nature Genetics have for the ... heart attack and coronary heart disease. In one of ... kind, the Myocardial Infarction Genetics Consortium identified nine precise ... three of them newly discovered; the investigators said that ...
... to be an international leader in personalized medicine and ... of Canadians and to reap the benefits of job ... http://www.cmaj.ca/cgi/rapidpdf/cmaj.1090199 released online today in CMAJ ( Canadian ... based on an individual,s genetic and health needs, rather ...
Cached Medicine News:Health News:One in Five Augustans With Type 2 Diabetes Mistakenly Believe That Being Obese or Overweight Can Positively Impact Their Disease 2Health News:One in Five Augustans With Type 2 Diabetes Mistakenly Believe That Being Obese or Overweight Can Positively Impact Their Disease 3Health News:Blood Drive Held in Honor of Sewell, NJ Resident - Ellie Koerner 2Health News:Last Chance! Be Smart--Don't Start! Entries Due by Feb. 27 2Health News:FDA approves ULORIC (febuxostat) for the chronic management of hyperuricemia in patients with gout 2Health News:FDA approves ULORIC (febuxostat) for the chronic management of hyperuricemia in patients with gout 3Health News:New genomic markers associated with risk of heart disease and early heart attack 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: